Werewolf Therapeutics’ Post

We extend our gratitude to Igor Puzanov, MD, of Roswell Park Comprehensive Cancer Center for his insightful review of our clinical data from the Phase 1/1b trial evaluating WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. These data reinforce the promise of our INDUKINE hypothesis, which suggests that potent cytokine-based immunotherapies can address difficult-to-treat tumors while minimizing the typical toxicities associated with Interleukin-2 (IL-2) therapy. Watch the MedPage Today story here: https://lnkd.in/e5SQKBVF Read more about WTX-124: https://lnkd.in/eEwKG2p4 #HOWL #ImmunoOncology #Cytokines #Cancer #Biotech #ASCO #ASCO24

Today Werewolf announced initial results from the Phase 1 clinical trial evaluating WTX-330, a systemically delivered, conditionally activated Interleukin-12 (IL-12) INDUKINE™ molecule for the treatment of solid tumors. These results validate our novel approach of developing conditionally activated cytokines as cancer therapies to improve outcomes for patients with hard-to-treat tumors. Read more here: https://lnkd.in/gfZxqWDu #HOWL #ImmunoOncology #Cytokines #Cancer #Biotech

During #NationalCancerSurvivorsMonth, we honor the incredible strength and courage of #cancer survivors. Your resilience inspires us every day. At Werewolf, we are humbled to be part of the journey toward conquering cancer. Through our relentless dedication to pioneering research, innovative therapies, and unwavering support, we stand alongside survivors and their families, offering hope, healing, and a promise of a brighter tomorrow. Learn more about our approach here: https://werewolftx.com/ Hear from survivors at https://lnkd.in/e6nPuHhB #HOWL #ImmunoOncology #Cytokines

Werewolf is proud to join the global immunotherapy community during #CancerImmunotherapyMonth in bringing awareness to the potential of immune-based #cancer therapies currently in development that have the potential to transform the treatment paradigm for patients living with cancer. At Werewolf, our technology is designed to unleash validated and proven proinflammatory mechanisms on tumors while preventing unwanted side effects on non-target tissue. We create systemically delivered targeted therapies that address the limitations of immuno-oncology. To learn more about our science and pipeline, check out this recent webcast announcing monotherapy and combination data from WTX-124 published at the American Society of Clinical Oncology (ASCO) Annual Meeting: https://lnkd.in/eEwd8nJr #HOWL #ImmunoOncology #Immunotherapy #Cytokines

Today at the American Society of Clinical Oncology (ASCO) Annual Meeting, we presented data from the dose-escalation portion of our Phase 1/1b trial evaluating WTX-124 as a single agent and in combination with pembrolizumab. Read more: https://lnkd.in/eEwKG2p4 Tune in to our webcast with company management and study investigator Justin Moser MD on Monday, June 3 at 8am ET to review these data. It can be accessed live at https://lnkd.in/eEwd8nJr   #ASCO24 #ASCO #HOWL #ImmunoOncology #Cytokines

Mark your calendars for Werewolf’s fireside chat at the 2024 Jefferies Global Healthcare Conference! Our President and CEO Daniel J. Hicklin, Ph.D., and our CMO Randi Isaacs, M.D., will be discussing our pipeline of next generation, transformative immuno-stimulatory medicines. Learn more: https://lnkd.in/g9JbnGWj #HOWL #JefferiesHealthcare #ImmunoOncology #Cytokines

Are you at #Immunology2024, the annual meeting of The American Association of Immunologists? Be sure to stop by our poster presentation TODAY from 2:15pm – 3:30pm at board #B906. We will be presenting on the development of conditionally active IL-10 INDUKINE™ molecules for the treatment of #IBD. Learn more: https://lnkd.in/eQJn97hH #HOWL #AAI2024 

At Werewolf, we stand united in our commitment to revolutionizing #cancer care through relentless research and innovation. This #NationalCancerResearchMonth, we join the American Association for Cancer Research in highlighting the importance of lifesaving research to the millions of people around the world affected by cancer. Our differentiation lies in our novel technology aimed at advancing #cytokines as immunotherapies for cancer. We recently presented preclinical data on development candidates WTX-518 and WTX-712 at #AACR2024. Our posters can be viewed here: https://lnkd.in/eKEuTxFX #NCRM24 #HOWL #ImmunoOncology

Exciting news! We're thrilled to announce that Werewolf has emerged victorious in Fierce Biotech's #FierceMadness: The Best Biotech Name Tournament! Amidst stiff competition and countless impressive contenders, our name stood out as a beacon of innovation, creativity, and industry prowess. This victory is a testament to the dedication and passion of our team, who consistently strive for excellence in all that we do. Thank you to all of our supporters and the courage of our patients who participate in our clinical trials — let's keep pushing boundaries to transform the lives of cancer patients! Read here: https://lnkd.in/eGYK3gV2 #HOWL